About Xencor (NASDAQ:XNCR)
Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody therapeutics to treat severe and life threatening diseases with unmet medical needs. It develops its antibody product candidates to treat autoimmune and allergic diseases, cancer, and other conditions. The company's product candidates include XmAb5871, an immune inhibitor, which is in Phase II clinical trial for the treatment of autoimmune diseases; and XmAb7195, an immune inhibitor that has been completed Phase I clinical trial for asthma and allergic diseases. Its product candidates also comprise XmAb14045, a bispecific oncology candidate, which is in Phase I clinical trial for the treatment of acute myeloid leukemia; XmAb13676 that is in Phase I clinical trial to treat B-cell malignancies; and XmAb18087, which is in Phase I clinical trial for neuroendocrine tumors and gastrointestinal stromal tumors. In addition, the company offers MOR208, an antibody drug, that in Phase III clinical trial to treat non-Hodgkin lymphomas, as well as in Phase II clinical trial for chronic lymphocytic leukemia; and AMG424, a bispecific CD38 x CD3 preclinical candidate for various myeloma. Further, it is developing bispecific antibodies to treat various cancers, such as XmAb20717, XmAb22841, and XmAb23104, which are in preclinical Phase. The company has collaboration and license agreement with Novartis Institutes for BioMedical Research, Inc. to develop and commercialize bispecific and other Fc engineered antibody drug candidates using its proprietary XmAb technologies and drug candidates, as well as MorphoSys Ag to develop and commercialize bispecific antibody product candidates; license agreement with Amgen Inc. to develop and commercialize bispecific antibody product candidates; and development and manufacturing services agreement with Catalent Pharma Solutions LLC. Xencor, Inc.was founded in 1997 and is headquartered in Monrovia, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:XNCR
CUSIPN/A
Phone626-305-5900
Debt
Debt-to-Equity RatioN/A
Current Ratio2.28%
Quick Ratio2.28%
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual Sales$35.71 million
Price / Sales45.44
Cash FlowN/A
Price / CashN/A
Book Value$6.01 per share
Price / Book4.97
Profitability
EPS (Most Recent Fiscal Year)($1.05)
Net Income$-48,920,000.00
Net Margins-137.35%
Return on Equity-16.62%
Return on Assets-12.06%
Miscellaneous
Employees114
Outstanding Shares54,300,000
Xencor (NASDAQ:XNCR) Frequently Asked Questions
What is Xencor's stock symbol?
Xencor trades on the NASDAQ under the ticker symbol "XNCR."
How were Xencor's earnings last quarter?
Xencor (NASDAQ:XNCR) posted its earnings results on Tuesday, February, 27th. The biopharmaceutical company reported ($0.25) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.27) by $0.02. The biopharmaceutical company had revenue of $10.94 million for the quarter, compared to analyst estimates of $15.65 million. Xencor had a negative net margin of 137.35% and a negative return on equity of 16.62%. View Xencor's Earnings History.
What price target have analysts set for XNCR?
6 brokers have issued 12 month price targets for Xencor's shares. Their predictions range from $28.00 to $39.00. On average, they anticipate Xencor's share price to reach $35.1667 in the next twelve months. View Analyst Ratings for Xencor.
What are Wall Street analysts saying about Xencor stock?
Here are some recent quotes from research analysts about Xencor stock:
- 1. According to Zacks Investment Research, "Xencor Inc. is a clinical-stage biopharmaceutical company. It develops antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer. Xencor Inc. is based in Monrovia, California. " (4/7/2018)
- 2. Cantor Fitzgerald analysts commented, "XmAb5871 likely the asset of greatest interest in 2018. The B cell-targeting MAb is being tested in patients with IgG4 related disease (IgG4-RD) and in patients with systemic lupus erythematosus (SLE) with Phase 3 testing for the former expected to start in 2Q18 and data from Phase 2 testing for the latter expected in 4Q18. Because the MAb modulates B cell activity but does not eliminate them, we believe the safety profile could be regarded to be superior as compared with other therapies, e.g., Rituxan." (3/29/2018)
Who are some of Xencor's key competitors?
Some companies that are related to Xencor include Array BioPharma (ARRY), Tesaro (TSRO), Ultragenyx Pharmaceutical (RARE), Emergent BioSolutions (EBS), Amicus Therapeutics (FOLD), Ascendis Pharma (ASND), Evotec A.G. (EVTCY), Clovis Oncology (CLVS), Ironwood Pharmaceuticals (IRWD), Supernus Pharmaceuticals (SUPN), Acadia Pharmaceuticals (ACAD), Akorn (AKRX), Puma Biotechnology (PBYI), Horizon Pharma (HZNP), Heron Therapeutics (HRTX), Global Blood Therapeutics (GBT), Portola Pharmaceuticals (PTLA) and AnaptysBio (ANAB).
Who are Xencor's key executives?
Xencor's management team includes the folowing people:
- Dr. Bassil I. Dahiyat Ph.D., Co-Founder, Chief Exec. Officer, Pres and Director (Age 48)
- Mr. John J. Kuch, VP of Fin. & Sec. (Age 59)
- Dr. John R. Desjarlais Ph.D., Chief Scientific Officer and Sr. VP of Research (Age 54)
- Dr. Edgardo Baracchini Jr., Ph.D., M.B.A., Chief Bus. Officer (Age 59)
- Dr. Paul A. Foster M.D., F.A.H.A., Chief Medical Officer and Sr. VP (Age 64)
Has Xencor been receiving favorable news coverage?
News stories about XNCR stock have been trending somewhat positive recently, Accern reports. The research firm identifies negative and positive news coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Xencor earned a coverage optimism score of 0.20 on Accern's scale. They also gave media coverage about the biopharmaceutical company an impact score of 45.38 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the near future.
How do I buy shares of Xencor?
Shares of XNCR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Xencor's stock price today?
One share of XNCR stock can currently be purchased for approximately $29.88.
How big of a company is Xencor?
Xencor has a market capitalization of $1.62 billion and generates $35.71 million in revenue each year. The biopharmaceutical company earns $-48,920,000.00 in net income (profit) each year or ($1.05) on an earnings per share basis. Xencor employs 114 workers across the globe.
How can I contact Xencor?
Xencor's mailing address is 111 WEST LEMON AVENUE, MONROVIA CA, 91016. The biopharmaceutical company can be reached via phone at 626-305-5900 or via email at [email protected]
MarketBeat Community Rating for Xencor (XNCR)
MarketBeat's community ratings are surveys of what our community members think about Xencor and other stocks. Vote "Outperform" if you believe XNCR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe XNCR will underperform the S&P 500 over the long term. You may vote once every thirty days.
Xencor (NASDAQ:XNCR) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
6 Wall Street analysts have issued ratings and price targets for Xencor in the last 12 months. Their average twelve-month price target is $35.1667, suggesting that the stock has a possible upside of 17.69%. The high price target for XNCR is $39.00 and the low price target for XNCR is $28.00. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 2.83 | 3.00 | 2.67 | 2.60 |
| Ratings Breakdown: | 0 Sell Rating(s)
1 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
2 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
2 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $35.1667 | $36.75 | $30.80 | $28.00 |
| Price Target Upside: | 17.69% upside | 17.49% upside | 54.00% upside | 36.72% upside |
Xencor (NASDAQ:XNCR) Consensus Price Target History
Xencor (NASDAQ:XNCR) Analyst Ratings History
Show:
(Data available from 4/22/2016 forward)
Xencor (NASDAQ:XNCR) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Xencor (NASDAQ XNCR) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 4.03%
Institutional Ownership Percentage: 68.82%
Xencor (NASDAQ XNCR) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 3/15/2018 | Edgardo Baracchini Jr | Insider | Sell | 40,000 | $30.89 | $1,235,600.00 | 40,000 |  |
| 3/5/2018 | Edgardo Baracchini Jr | Insider | Sell | 20,000 | $29.59 | $591,800.00 | 10,000 | |
| 3/2/2018 | Edgardo Baracchini Jr | Insider | Sell | 10,000 | $29.60 | $296,000.00 | 10,000 | |
| 2/27/2018 | Edgardo Baracchini Jr | Insider | Sell | 20,000 | $29.64 | $592,800.00 | 20,000 | |
| 2/22/2018 | Paul A Foster | Insider | Sell | 10,000 | $26.03 | $260,300.00 | 12,419 | |
| 2/16/2018 | Paul A Foster | Insider | Sell | 5,000 | $25.01 | $125,050.00 | 7,419 | |
| 12/14/2017 | John S Stafford III | Major Shareholder | Buy | 9,215 | $20.76 | $191,303.40 | | |
| 12/12/2017 | John S Stafford III | Major Shareholder | Buy | 6,215 | $20.72 | $128,774.80 | | |
| 11/28/2017 | John S Stafford III | Major Shareholder | Buy | 15,374 | $19.86 | $305,327.64 | | |
| 11/24/2017 | John S Stafford III | Major Shareholder | Buy | 5,349 | $19.85 | $106,177.65 | | |
| 11/10/2017 | John S Stafford III | Major Shareholder | Buy | 324 | $19.90 | $6,447.60 | | |
| 11/8/2017 | John S Stafford III | Major Shareholder | Buy | 3,400 | $19.89 | $67,626.00 | | |
| 11/6/2017 | John S Stafford III | Major Shareholder | Buy | 305 | $19.92 | $6,075.60 | | |
| 11/2/2017 | John S Stafford III | Major Shareholder | Buy | 50,000 | $19.58 | $979,000.00 | | |
| 10/31/2017 | John S Stafford III | Major Shareholder | Buy | 13,700 | $19.81 | $271,397.00 | | |
| 10/27/2017 | John S Stafford III | Major Shareholder | Buy | 150,000 | $19.81 | $2,971,500.00 | | |
| 10/25/2017 | John S Stafford III | Major Shareholder | Buy | 24,653 | $20.01 | $493,306.53 | | |
| 8/22/2017 | John S Stafford III | Major Shareholder | Buy | 41,016 | $19.69 | $807,605.04 | | |
| 8/18/2017 | John S Stafford III | Major Shareholder | Buy | 43,500 | $19.93 | $866,955.00 | | |
| 8/17/2017 | John S Stafford III | Major Shareholder | Buy | 79,035 | $20.47 | $1,617,846.45 | | |
| 8/16/2017 | John S Stafford III | Major Shareholder | Buy | 25,000 | $20.96 | $524,000.00 | | |
| 8/11/2017 | John S Stafford III | Major Shareholder | Buy | 27,000 | $21.13 | $570,510.00 | | |
| 6/28/2017 | John S Stafford III | Major Shareholder | Buy | 6,000 | $19.94 | $119,640.00 | | |
| 6/16/2017 | John S Stafford III | Major Shareholder | Buy | 1,500 | $19.67 | $29,505.00 | | |
| 6/14/2017 | Bruce L A Carter | Director | Sell | 20,000 | $20.61 | $412,200.00 | 48,880 | |
| 6/2/2017 | Bruce L A Carter | Director | Sell | 2,366 | $22.00 | $52,052.00 | 68,578 | |
| 5/26/2017 | Bruce L A Carter | Director | Sell | 12,400 | $22.19 | $275,156.00 | 83,344 | |
| 5/2/2017 | Edgardo Baracchini Jr | Insider | Sell | 10,568 | $26.01 | $274,873.68 | 9,818 | |
| 4/27/2017 | Edgardo Baracchini Jr | Insider | Sell | 904 | $26.04 | $23,540.16 | 904 | |
| 3/16/2017 | John J. Kuch | VP | Sell | 15,000 | $24.42 | $366,300.00 | | |
| 3/8/2017 | Edgardo Baracchini Jr | Insider | Sell | 1,821 | $25.00 | $45,525.00 | 1,821 | |
| 12/6/2016 | John S Stafford III | Major Shareholder | Sell | 63,061 | $27.71 | $1,747,420.31 | | |
| 9/28/2016 | Edgardo Baracchini Jr | Insider | Sell | 10,000 | $25.35 | $253,500.00 | 10,000 | |
| 9/27/2016 | John S Stafford III | Major Shareholder | Sell | 40,000 | $25.72 | $1,028,800.00 | | |
| 9/2/2016 | Edgardo Baracchini Jr | Insider | Sell | 10,000 | $21.06 | $210,600.00 | 10,000 | |
| 8/30/2016 | Bassil I Dahiyat | Insider | Sell | 40,000 | $21.80 | $872,000.00 | 341,128 | |
| 8/26/2016 | John S Stafford III | Major Shareholder | Sell | 24,351 | $21.48 | $523,059.48 | | |
| 8/24/2016 | John J Kuch | VP | Sell | 25,000 | $21.95 | $548,750.00 | 92,078 | |
| 8/23/2016 | John R Desjarlais | VP | Sell | 16,294 | $21.73 | $354,068.62 | 28,640 | |
| 8/23/2016 | John S Stafford III | Major Shareholder | Sell | 96,828 | $21.73 | $2,104,072.44 | | |
| 8/16/2016 | Bassil I Dahiyat | Insider | Sell | 45,886 | $22.06 | $1,012,245.16 | 365,321 | |
| 8/15/2016 | Bruce L A Carter | Director | Sell | 3,400 | $22.67 | $77,078.00 | 10,000 | |
| 8/15/2016 | John S Stafford III | Major Shareholder | Sell | 10,000 | $23.06 | $230,600.00 | | |
| 8/11/2016 | John S Stafford III | Major Shareholder | Sell | 30,500 | $21.87 | $667,035.00 | 7,500 | |
| 8/10/2016 | Edgardo Baracchini Jr | Insider | Sell | 2,500 | $21.83 | $54,575.00 | 2,500 | |
| 8/3/2016 | Edgardo Baracchini, Jr. | Insider | Sell | 4,528 | $20.00 | $90,560.00 | | |
| 8/3/2016 | John R. Desjarlais | VP | Sell | 5,905 | $20.00 | $118,100.00 | | |
| 7/11/2016 | Edgardo Baracchini Jr | Insider | Sell | 1,250 | $18.13 | $22,662.50 | 5,778 | |
| 6/28/2016 | Edgardo Baracchini Jr | Insider | Sell | 1,250 | $15.10 | $18,875.00 | 5,778 | |
| 5/24/2016 | Bassil I Dahiyat | CEO | Sell | 45,886 | $13.00 | $596,518.00 | 358,186 | |
| 4/7/2016 | Edgardo Baracchini Jr | Insider | Sell | 3,750 | $15.00 | $56,250.00 | 8,278 | |
| 3/17/2016 | Bassil I Dahiyat | CEO | Sell | 45,886 | $11.02 | $505,663.72 | 289,358 | |
| 3/3/2016 | John R Desjarlais | VP | Sell | 14,260 | $12.01 | $171,262.60 | 57,709 | |
| 2/1/2016 | John S Stafford III | Major Shareholder | Sell | 25 | $10.79 | $269.75 | 5,264,740 | |
| 1/29/2016 | John S Stafford III | Major Shareholder | Buy | 25 | $10.83 | $270.75 | 5,264,740 | |
| 1/4/2016 | John R. Desjarlais | VP | Sell | 1,100 | $14.13 | $15,543.00 | 27,323 | |
| 12/17/2015 | John J Kuch | VP | Sell | 4,781 | $14.89 | $71,189.09 | 10,650 | |
| 12/16/2015 | Paul A. Foster | insider | Sell | 6,025 | $15.01 | $90,435.25 | 3,602 | |
| 12/3/2015 | John S. Stafford III | Director | Sell | 30,000 | $15.13 | $453,900.00 | 5,264,740 | |
| 11/25/2015 | Edgardo Baracchini, Jr. | insider | Sell | 2,500 | $15.00 | $37,500.00 | | |
| 9/3/2015 | John S Stafford III | Director | Sell | 10,000 | $17.22 | $172,200.00 | 77,500 | |
| 9/1/2015 | Edgardo Baracchini, Jr. | insider | Sell | 1,250 | $16.49 | $20,612.50 | | |
| 7/6/2015 | John S Stafford III | Director | Sell | 10,000 | $22.29 | $222,900.00 | | |
| 7/1/2015 | Edgardo Baracchini Jr | Insider | Sell | 2,500 | $22.24 | $55,600.00 | | |
| 6/16/2015 | John S Stafford III | Director | Sell | 20,000 | $20.35 | $407,000.00 | | |
| 6/15/2015 | Bruce L A Carter | Director | Sell | 10,000 | $19.21 | $192,100.00 | | |
| 6/15/2015 | Edgardo Baracchini Jr | Insider | Sell | 1,277 | $19.85 | $25,348.45 | | |
| 6/12/2015 | John J Kuch | VP | Sell | 8,756 | $19.35 | $169,428.60 | | |
| 6/12/2015 | John S Stafford III | Director | Sell | 250,000 | $19.00 | $4,750,000.00 | | |
| 6/3/2015 | John S Stafford III | Director | Sell | 10,000 | $18.76 | $187,600.00 | | |
| 6/1/2015 | Edgardo Baracchini Jr | Insider | Sell | 1,250 | $18.14 | $22,675.00 | | |
| 5/26/2015 | John S Stafford III | Director | Sell | 10,000 | $17.01 | $170,100.00 | | |
| 5/15/2015 | Edgardo Baracchini Jr | Insider | Sell | 1,604 | $15.00 | $24,060.00 | | |
| 8/11/2014 | John S Stafford III | Director | Sell | 124,000 | $9.37 | $1,161,880.00 | | |
| 12/6/2013 | John S Stafford III | Director | Buy | 275,000 | $5.50 | $1,512,500.00 | | |
(Data available from 1/1/2013 forward)
Xencor (NASDAQ XNCR) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Xencor (XNCR) Presents Preclinical Data on XmAb24306 at AACR
www.streetinsider.com - April 19 at 8:46 AM |
 | Xencor Presents Preclinical Data on XmAb®24306, Introduces XmAb® IL15 Bispecific Platform at American Association for Cancer Research (AACR) 2018 Annual Meeting
finance.yahoo.com - April 18 at 5:18 PM |
 | Brokerages Anticipate Xencor (XNCR) Will Post Quarterly Sales of $3.52 Million
www.americanbankingnews.com - April 18 at 4:16 AM |
| Xencor (XNCR) Expected to Announce Earnings of -$0.45 Per Share
www.americanbankingnews.com - April 16 at 5:16 AM |
| What Do Analysts Think About Xencor Inc’s (NASDAQ:XNCR) Earnings Trajectory?
finance.yahoo.com - April 12 at 9:27 AM |
 | Commit To Purchase Xencor At $22.50, Earn 9.3% Annualized Using Options
www.nasdaq.com - April 11 at 5:03 PM |
| Xencor (XNCR) Rating Increased to Hold at Zacks Investment Research
www.americanbankingnews.com - April 7 at 4:27 PM |
| Xencor (XNCR) Stock Rating Lowered by ValuEngine
www.americanbankingnews.com - April 6 at 11:39 AM |
| Cantor Fitzgerald Weighs in on Xencor's FY2018 Earnings (XNCR)
www.americanbankingnews.com - April 6 at 7:24 AM |
| Xencor (XNCR) PT Lowered to $28.00 at Nomura
www.americanbankingnews.com - April 5 at 5:46 PM |
| ValuEngine Upgrades Xencor (XNCR) to "Buy"
www.americanbankingnews.com - April 2 at 10:26 PM |
| Zacks: Brokerages Expect Xencor Inc (XNCR) Will Post Quarterly Sales of $2.78 Million
www.americanbankingnews.com - April 1 at 4:20 AM |
| Xencor Inc (XNCR) Receives Average Rating of "Buy" from Analysts
www.americanbankingnews.com - April 1 at 1:36 AM |
| Edited Transcript of XNCR earnings conference call or presentation 27-Feb-18 9:30pm GMT
finance.yahoo.com - March 30 at 5:05 PM |
| -$0.49 EPS Expected for Xencor Inc (XNCR) This Quarter
www.americanbankingnews.com - March 30 at 9:27 AM |
| Xencor (XNCR) Stock Rating Reaffirmed by Cantor Fitzgerald
www.americanbankingnews.com - March 29 at 9:36 PM |
| Xencor (XNCR) Given Outperform Rating at Leerink Swann
www.americanbankingnews.com - March 28 at 9:16 AM |
| Xencor Inc (XNCR) Expected to Earn Q1 2018 Earnings of ($0.55) Per Share
www.americanbankingnews.com - March 28 at 6:38 AM |
| Xencor (XNCR) Rating Increased to Buy at BidaskClub
www.americanbankingnews.com - March 24 at 11:46 PM |
| Xencor (XNCR) Receives Overweight Rating from Cantor Fitzgerald
www.americanbankingnews.com - March 24 at 2:12 PM |
| FY2019 EPS Estimates for Xencor Inc Increased by Analyst (XNCR)
www.americanbankingnews.com - March 22 at 2:32 PM |
| Equities Analysts Offer Predictions for Xencor Inc's Q1 2019 Earnings (XNCR)
www.americanbankingnews.com - March 21 at 10:58 AM |
| Xencor to Present at 17th Annual Needham Healthcare Conference
finance.yahoo.com - March 21 at 9:41 AM |
| Xencor (XNCR) Plans 5M Share Public Offering of Common Stock
www.streetinsider.com - March 20 at 4:52 PM |
 | BRIEF-Xencor Files For Potential Mixed Shelf Offering
www.reuters.com - March 20 at 9:02 AM |
| BRIEF-Xencor Announces Proposed Public Offering Of Common Stock
www.reuters.com - March 19 at 4:52 PM |
| Xencor (XNCR) Given New $39.00 Price Target at Wedbush
www.americanbankingnews.com - March 19 at 10:57 AM |
| Xencor (XNCR) Raised to "Hold" at Zacks Investment Research
www.americanbankingnews.com - March 17 at 10:31 AM |
| Edgardo Baracchini, Jr. Sells 40,000 Shares of Xencor Inc (XNCR) Stock
www.americanbankingnews.com - March 16 at 7:16 PM |
| Xencor (XNCR) Rating Increased to Strong-Buy at BidaskClub
www.americanbankingnews.com - March 10 at 4:04 PM |
| Xencor (XNCR) Cut to Sell at Zacks Investment Research
www.americanbankingnews.com - March 8 at 6:58 PM |
| FY2018 EPS Estimates for Xencor Inc Cut by Cantor Fitzgerald (XNCR)
www.americanbankingnews.com - March 7 at 11:50 AM |
| Xencor Inc (XNCR) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - March 7 at 1:50 AM |
| Insider Selling: Xencor Inc (XNCR) Insider Sells 10,000 Shares of Stock
www.americanbankingnews.com - March 5 at 9:32 PM |
| Edgardo Baracchini, Jr. Sells 20,000 Shares of Xencor Inc (XNCR) Stock
www.americanbankingnews.com - March 5 at 9:30 PM |
| Wedbush Weighs in on Xencor Inc's Q1 2018 Earnings (XNCR)
www.americanbankingnews.com - March 5 at 1:10 AM |
| What Do Investors Need To Know About Xencor Inc’s (NASDAQ:XNCR) Growth?
finance.yahoo.com - March 3 at 5:53 PM |
| Research Analysts Set Expectations for Xencor Inc's FY2022 Earnings (XNCR)
www.americanbankingnews.com - March 2 at 5:32 PM |
| Leerink Swann Comments on Xencor Inc's Q1 2018 Earnings (XNCR)
www.americanbankingnews.com - March 2 at 9:10 AM |
| Xencor Inc (XNCR) Insider Sells $592,800.00 in Stock
www.americanbankingnews.com - March 1 at 9:32 PM |
| Consolidated Research: 2018 Summary Expectations for Sonic Automotive, Xencor, Gevo, OSI, Buckeye Partners, and Glatfelter — Fundamental Analysis, Key Performance Indications
finance.yahoo.com - March 1 at 8:40 AM |
| Xencor Reports Fourth Quarter and Full Year 2017 Financial Results
finance.yahoo.com - February 27 at 5:31 PM |
| Analysts Expect Xencor Inc (XNCR) Will Announce Quarterly Sales of $15.65 Million
www.americanbankingnews.com - February 26 at 5:52 AM |
| Brokerages Anticipate Xencor Inc (XNCR) to Announce -$0.27 EPS
www.americanbankingnews.com - February 24 at 8:06 AM |
| Xencor Inc (XNCR) Insider Sells $260,300.00 in Stock
www.americanbankingnews.com - February 22 at 9:38 PM |
| Cantor Fitzgerald Initiates Coverage on Xencor (XNCR)
www.americanbankingnews.com - February 22 at 4:24 PM |
| Xencor Doses First Patient in Phase 1 Study of XmAb®18087 Bispecific Tumor Targeting Antibody for the Treatment of Neuroendocrine Tumors and Gastrointestinal Stromal Tumors
finance.yahoo.com - February 22 at 8:47 AM |
| Xencor (XNCR) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - February 20 at 4:50 PM |
| Xencor to Host Fourth Quarter and Full Year 2017 Financial Results Webcast and Conference Call on February 27, 2018
finance.yahoo.com - February 20 at 8:39 AM |
| Xencor (XNCR) Raised to Hold at BidaskClub
www.americanbankingnews.com - February 17 at 9:22 PM |
Xencor (NASDAQ:XNCR) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Xencor (NASDAQ:XNCR) Income Statement, Balance Sheet and Cash Flow Statement
Xencor (NASDAQ XNCR) Stock Chart for Sunday, April, 22, 2018
Loading chart…
